stockrowKiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.
- Revenue
- +58.1%
- EPS
- +142.2%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
Follow KNSA
Alert me
Kiniksa Pharmaceuticals International, plc (KNSA) Operating cash flow
Kiniksa Pharmaceuticals International, plc's operating cash flow for fiscal 2025 was $138.0M, up 437.1% from $25.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $198.8M. Over the past ten years it has ranged from −$158.4M (fiscal 2019) to $138.0M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 6 consecutive fiscal years. Kiniksa Pharmaceuticals International, plc ranks 21st of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $138.0M | 437.14% |
| FY2024 | $25.7M | 93.14% |
| FY2023 | $13.3M | 129.05% |
| FY2022 | $5.8M | — |
| FY2021 | −$126.3M | — |
| FY2020 | −$136.5M | — |
| FY2019 | −$158.4M | — |
| FY2018 | −$81.0M | — |
| FY2017 | −$50.2M | — |
| FY2016 | −$21.9M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $47.5M | 0.75% |
| Jun 2026 | $47.2M | (5.98%) |
| Mar 2026 | $50.2M | (6.86%) |
| Dec 2025 | $53.9M | 60.03% |
| 35 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ELAN Elanco Animal Health Incorporated compare | $617.0M |
| LNTH Lantheus Holdings, Inc. compare | $409.5M |
| RDY Dr. Reddy's Laboratories Ltd compare | $313.0M |
| HIMS Hims & Hers Health, Inc. compare | $263.5M |
| ALKS Alkermes plc compare | $243.0M |
| KNSA Kiniksa Pharmaceuticals International, plc | $198.8M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $180.6M |
| LQDA Liquidia Corporation compare | $167.7M |
| SUPN Indivior Pharmaceuticals Inc. compare | $96.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on KNSA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement